SCHEMBL4616210

SCHEMBL4616210

CC(C)c1ccc(S(=O)(=O)c2ccc(F)cc2)cc1S(=O)(=O)NC1CCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.46
RECQL P46063 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ALDH1A1 P00352 4/20 0.44
HPGD P15428 2/20 0.44
HTT P42858 2/20 0.44
TSHR P16473 2/20 0.44
LMNA P02545 2/20 0.44
HSD17B10 Q99714 1/20 0.44
MAPT P10636 1/20 0.44
HTR1A P08908 5/20 0.44
HTR7 P34969 5/20 0.44
DRD2 P14416 2/20 0.44
HTR6 P50406 2/20 0.44
GAA P10253 1/20 0.44
KMT2A Q03164 1/20 0.44
SFRP1 Q8N474 2/20 0.43
WNT3 P56703 1/20 0.43
HTR2A P28223 1/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4617737 0.99 ALDH1A1 (0.46) KDM4ERECQLSMN1; SMN2ALDH1A1HPGD
SCHEMBL4617601 0.98 HTR1A (0.44) KDM4ERECQLSMN1; SMN2ALDH1A1HPGD
SCHEMBL4617920 0.95 HTR1A (0.45) HTR1AHTR7DRD2HTR6KMT2A
SCHEMBL6103313 0.90 HTR1A (0.42) HTR1AHTR7DRD2HTR6KMT2A
SCHEMBL4619043 0.90 HTR1A (0.42) HTR1AHTR7DRD2HTR6KMT2A
SCHEMBL4617906 0.90 SFRP1 (0.56) HTR1AHTR7DRD2HTR6SFRP1
SCHEMBL4618933 0.89 HTR1A (0.41) HTR1AHTR7DRD2HTR6KMT2A
SCHEMBL4615580 0.89 IKBKB (0.42) HTR1AHTR7DRD2HTR6KMT2A
SCHEMBL4617481 0.88 KDM4E (0.46) KDM4ERECQLSMN1; SMN2ALDH1A1HPGD
SCHEMBL6102396 0.85 SFRP1 (0.51) SFRP1WNT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP claimed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US claimed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 KDM4E 3044/4885RECQL 4498/4885SMN1; SMN2 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.